glp 1 chronic kidney disease Glucagon-like Peptide-1 Receptor Agonists and Diabetic Disease: From Bench to Bed-Side GLP-1 receptor agonists in patients

GLP controls hunger and cravings

Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease

doi: 10.1161/CIRCULATIONAHA.121.055459

This project was funded by the Israel Science Foundation grant 967/19 and ERC StG 803526 (to DBZ)

Bc s s nh gi h s lm sng tng th ca bn trc khi a ra khuyn ngh liu phng php iu tr GLP-1 c ph hp vi bn hay khng

Cold-chain integrity, consistent supply availability, and digital support for adherence and refill management have become critical differentiators as therapies scale into direct-to-patient delivery models